This review discusses the emerging roles of ferroptosis, pyroptosis, and necroptosis in anti-PD-1/PD-L1 cancer immunotherapy. Immune checkpoint inhibitors (ICIs), particularly anti-PD-1 and anti-PD-L1 antibodies, have shown clinical efficacy in various cancers but are effective in only a subset of patients. The review highlights that combining ICIs with non-apoptotic regulated cell death (RCD) inducers can enhance their antitumor efficacy. Ferroptosis, a iron-dependent form of RCD, pyroptosis, an inflammatory form of cell death, and necroptosis, a form of programmed necrosis, are discussed in detail. These forms of RCD modify the tumor microenvironment (TME) and enhance the efficacy of cancer therapies. The review also emphasizes the synergy between nanomaterials and PD-1/PD-L1 inhibitors in inducing non-apoptotic RCD in different cancer types. Additionally, targeting cell death signaling pathways in combination with anti-PD1/PD-L1 therapies holds promise as a prospective immunotherapy strategy for tumor treatment. The review concludes by highlighting the potential of combining anti-PD1/PD-L1 therapy with RCD mediators to improve the efficacy and safety of immunotherapy.This review discusses the emerging roles of ferroptosis, pyroptosis, and necroptosis in anti-PD-1/PD-L1 cancer immunotherapy. Immune checkpoint inhibitors (ICIs), particularly anti-PD-1 and anti-PD-L1 antibodies, have shown clinical efficacy in various cancers but are effective in only a subset of patients. The review highlights that combining ICIs with non-apoptotic regulated cell death (RCD) inducers can enhance their antitumor efficacy. Ferroptosis, a iron-dependent form of RCD, pyroptosis, an inflammatory form of cell death, and necroptosis, a form of programmed necrosis, are discussed in detail. These forms of RCD modify the tumor microenvironment (TME) and enhance the efficacy of cancer therapies. The review also emphasizes the synergy between nanomaterials and PD-1/PD-L1 inhibitors in inducing non-apoptotic RCD in different cancer types. Additionally, targeting cell death signaling pathways in combination with anti-PD1/PD-L1 therapies holds promise as a prospective immunotherapy strategy for tumor treatment. The review concludes by highlighting the potential of combining anti-PD1/PD-L1 therapy with RCD mediators to improve the efficacy and safety of immunotherapy.